NCT05265429unknownrecruiting

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Dana-Farber Cancer Institute

ClinicalTrials.gov

500

Enrollment · estimated

Countries · 4 sites

2027-08

Primary completion

10 mo ago

Record updated

Commercial relevance

No explicit biomarker / molecular-testing language identified in the public record.

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
32/100
Opportunity
New unknown trial NCT05265429 posted by Dana-Farber Cancer Institute: "Biology of Young Lung Cancer Study: The YOUNG LUNG Study".
ClinicalTrials.gov record updated 314 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Age 45 and under at lung cancer diagnosis
* Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
* Provision of written informed consent
* Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
* Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent

Exclusion Criteria:

* Individuals who decline to sign consent
* Individuals who are unable to give consent or assent and are without a designated healthcare proxy
* Compromise of patient diagnosis or staging if tissue is used for research